A novel triple-agonist incretin peptide simultaneously targeting GIP, GLP-1, and glucagon receptors, investigated for multi-receptor metabolic pathway modulation in obesity and energy homeostasis research. For research use only.
Select options
This product has multiple variants. The options may be chosen on the product page
A synthetic GHRH analog featuring a trans-3-hexenoic acid modification, investigated for targeted stimulation of pulsatile growth hormone release and downstream lipolytic pathway activation. For research use only.